M&T Bank’s Cytek Biosciences CTKB Stock Holding History

M&T Bank’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,308	Closed	-$45K	–	1793
2026 Q1	$45K	Buy	10,308 +51	+0.5%	+$241	﹤0.01%	1675
2025 Q4	$51.8K	Buy	+10,257	New	+$47.6K	﹤0.01%	1651

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

M&T Bank's CTKB Position: Q2 2026 in Review

M&T Bank sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 10,308 shares — an estimated $45K sold.

M&T Bank first reported a position in CTKB in Q4 2025 and held it in 2 quarters. The position peaked at $51.8K in Q4 2025. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

M&T Bank reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
M&T Bank sold 10,308 Cytek Biosciences shares in Q2 2026, an estimated $45K.
M&T Bank first reported a position in Cytek Biosciences in Q4 2025 and held it in 2 quarters.
M&T Bank's Cytek Biosciences position peaked at $51.8K in Q4 2025.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.